Spine-Rad™ Cement is designed to provide local, targeted irradiation to assist in the prevention of tumor progression in the surrounding bone, while simultaneously restoring bone strength. When used in the spine, Spine-Rad™ Cement combines and simplifies the current two-step process for treatment of spinal tumors—vertebroplasty or kyphoplasty followed by external beam radiation therapy (EBRT). The product concept is analogous to the internally-targeted treatment of breast and prostate cancer tumors using brachytherapy techniques.
Bone-Rad Therapeutics, Inc. is a Delaware corporation whose objective is to develop and market Spine-Rad™ Cement as an innovative, improved, and cost-effective treatment paradigm in the management of tumors in bone.
January 2, 2017
Inventors at Bone-Rad have received the Notice of Allowance for their second patent in November 2016. This patent covers the method of treating tumors anywhere (not just tumors in bone) using radioactive cement, where the dose to the tissue is independent of the implanted volume of cement. The first patent (Patent No. 9,198,989) issued on Dec. 1, 2015 and covers the method for making the radioactive bone cement with the correct therapeutic properties. Together, these patents protect the unique dosimetry of this cement which makes the dose delivered to the tumor independent of the volume of cement and the amount of radioactivity that is injected. This property makes brachytherapy with Spine-Rad Cement much simpler to plan and to use than conventional brachytherapy techniques which use seeds. There are no brachytherapy treatments for bone on the market.
I am very excited about the potential that Spine-Rad™ Cement can offer to improve the care of patients with primary or metastatic disease in bone. This technology can significantly improve life expectancy, as well as the quality of life of these patients. As a physician and orthopaedic surgeon, it brings me great satisfaction to offer the expertise and scientific knowledge of myself and our phenomenal Bone-Rad team of experts in a constant effort to improve and extend the quality of life of cancer patients. This is our mission and promise to you.
Harry B. Skinner, M.D., Ph.D.
Co-Founder and Board Member
Bone-Rad Therapeutics, Inc.